Dr. Reddy's Laboratories Limited ("Dr. Reddy's") has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited ("Takeda") for Qdenga® in the private market in India. The agreement was executed on September 18, 2026.

Key Agreement Details

  • Product: Qdenga®, a dengue vaccine developed by Takeda to protect against all four dengue virus serotypes
  • Market Scope: Exclusive rights for Dr. Reddy's in the private market in India
  • Geographic Scope: Domestic (India)
  • Responsibilities: Dr. Reddy's will be exclusively responsible for distribution and marketing of Qdenga® in the private market
  • Takeda's Retained Rights: Commercialization rights in the public market in India, plus manufacturing and importation responsibilities
  • Relationship Status: Takeda is not a related party to Dr. Reddy's or any of its promoter/promoter group/group companies

Timeline and Availability

  • The vaccine is anticipated to become available in the first half of 2027
  • Availability is subject to completion of applicable processes with local authorities

Strategic Rationale

The partnership is aligned with Dr. Reddy's strategy to strengthen its vaccines business in India and supports broader public health efforts aimed at addressing the significant burden of dengue in India. The collaboration combines Takeda's global dengue and vaccine expertise with Dr. Reddy's extensive healthcare network and commercial reach across India.

Additional Context

  • Dengue cases in India have increased 11-fold over the past two decades
  • All four dengue virus serotypes (DENV-1 to DENV-4) are co-circulating across multiple regions in India
  • The World Health Organization has recommended the vaccine without pre-vaccination screening for use in high endemic countries
  • The vaccine has been approved in 43 countries including India, with more than 32 million doses distributed worldwide

Product Information

QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine built on a DENV-2 backbone with structural proteins from DENV-1, DENV-3, and DENV-4. The vaccine is administered as a two-dose regimen, given three months apart.

Financial Impact

Financial impact not quantified in the disclosure.